Tumour vascular targeting
暂无分享,去创建一个
[1] M. Uesugi,et al. [Discovering high-affinity ligands for proteins: SAR by NMR]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.
[2] K. Wüthrich,et al. NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis. , 1999, Structure.
[3] W. Woglom. A Critique of Tumor Resistance , 1922 .
[4] J. Healey,et al. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[5] M. Maio,et al. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] Fulvio Magni,et al. Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) , 2000, Nature Biotechnology.
[7] Dario Neri,et al. In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature , 2005, Nature Methods.
[8] C. Sheehan,et al. Prognostic factors in prostate cancer. , 2003, American journal of clinical pathology.
[9] H. Dvorak,et al. Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor. , 1996, European journal of cancer.
[10] L. Zardi,et al. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors , 1989, The Journal of cell biology.
[11] P. Janmey,et al. Involvement of phosphatidylinositol 4,5-bisphosphate in phosphatidylserine exposure in platelets: use of a permeant phosphoinositide-binding peptide. , 2001, Biochemistry.
[12] L. Zardi,et al. Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening. , 2001, Nucleic acids research.
[13] C. Milstein,et al. Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.
[14] Borivoj Vojnovic,et al. Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy. , 2005, Advanced drug delivery reviews.
[15] P. Carmeliet. Angiogenesis in health and disease , 2003, Nature Medicine.
[16] R. Brekken,et al. Vascular endothelial growth factor as a marker of tumor endothelium. , 1998, Cancer research.
[17] Lukasz Huminiecki,et al. In Silico Cloning of Novel Endothelial-Specific Genes , 2000 .
[18] Dario Neri,et al. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin , 2001, European Journal of Nuclear Medicine.
[19] D. Neri,et al. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy. , 2004, Biochemistry.
[20] J. Denekamp,et al. Endothelial-cell proliferation in experimental tumours. , 1982, British Journal of Cancer.
[21] D. Neri,et al. Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study , 2004, Proteomics.
[22] R. Begent,et al. Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37°C , 2004 .
[23] G. Viale,et al. Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. , 1999, The American journal of pathology.
[24] Yan Li,et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy , 2004, Nature.
[25] B. Hogan,et al. Cloning and characterization of developmental endothelial locus-1: An embryonic endothelial cell protein that binds the αvβ3 integrin receptor , 1997 .
[26] H. Kosmehl,et al. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. , 2001, Cancer research.
[27] D. Vestweber,et al. Biochemical Characterization and Molecular Cloning of a Novel Endothelial-Specific Sialomucin , 1999 .
[28] R. Schwendener,et al. Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes , 2002, British Journal of Cancer.
[29] W. Richards,et al. Dll4, a novel Notch ligand expressed in arterial endothelium. , 2000, Genes & development.
[30] A. Pini,et al. Design and Use of a Phage Display Library , 1998, The Journal of Biological Chemistry.
[31] W. Stanford,et al. Expression trapping: identification of novel genes expressed in hematopoietic and endothelial lineages by gene trapping in ES cells. , 1998, Blood.
[32] N. Bander,et al. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. , 2003, Seminars in oncology.
[33] R. Hynes,et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. , 2003, Cancer cell.
[34] J. Minna,et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. , 2000, Cancer research.
[35] A. Pini,et al. Phage antibodies with pan‐species recognition of the oncofoetal angiogenesis marker fibronectin ED‐B domain , 1996, International journal of cancer.
[36] G. Winter,et al. Making antibodies by phage display technology. , 1994, Annual review of immunology.
[37] Ryan Park,et al. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[38] L. Zardi,et al. Lack of specificity of endoglin expression for tumor blood vessels , 2001, International journal of cancer.
[39] S. Ran,et al. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. , 2002, Cancer research.
[40] H. Kosmehl,et al. mRNA expression and protein distribution of the unspliced tenascin‐C isoform in prostatic adenocarcinoma , 2004, The Journal of pathology.
[41] F. Eisenhaber,et al. Molecular Cloning and Characterization of Endosialin, a C-type Lectin-like Cell Surface Receptor of Tumor Endothelium* , 2001, The Journal of Biological Chemistry.
[42] David R. Liu,et al. DNA-Templated Organic Synthesis and Selection of a Library of Macrocycles , 2004, Science.
[43] V. Reuter,et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.
[44] Michael Streit,et al. Angiogenesis, lymphangiogenesis, and melanoma metastasis , 2003, Oncogene.
[45] S. Kumar,et al. A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues , 1993, International journal of cancer.
[46] C. Halin,et al. Tumor‐targeting properties of antibody–vascular endothelial growth factor fusion proteins , 2002, International journal of cancer.
[47] D. Spencer,et al. A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex. , 2001, Cancer research.
[48] Michael Gorn,et al. Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. , 2002, Genomics.
[49] Dario Neri,et al. Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform , 1997, Nature Biotechnology.
[50] K. Alitalo,et al. Role of lymphangiogenic factors in tumor metastasis. , 2004, Biochimica et biophysica acta.
[51] Angelo Corti,et al. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. , 2002, The Journal of clinical investigation.
[52] C. Isacke,et al. Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium , 2005, FEBS letters.
[53] Iris Verel,et al. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head‐and‐neck cancer xenografts , 2002, International journal of cancer.
[54] N. Bander,et al. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen , 2002, Prostate Cancer and Prostatic Diseases.
[55] Franklin Peale,et al. In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set. , 2002, Physiological genomics.
[56] Carlo Giussani,et al. Combinatorial Administration of Molecules That Simultaneously Inhibit Angiogenesis and Invasion Leads to Increased Therapeutic Efficacy in Mouse Models of Malignant Glioma , 2004, Clinical Cancer Research.
[57] T. N. Campbell,et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[58] K. Sekiguchi,et al. Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro. , 2002, Cancer research.
[59] G. Giuliani,et al. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[60] Milind Rajopadhye,et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. , 2002, Cancer research.
[61] M E Hammond,et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. , 2000, Archives of pathology & laboratory medicine.
[62] R. Barrett,et al. Increased potency of an erythropoietin peptide mimetic through covalent dimerization , 1997, Nature Biotechnology.
[63] R Pasqualini,et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.
[64] Christopher A. Jones,et al. Robo4 is a vascular-specific receptor that inhibits endothelial migration. , 2003, Developmental biology.
[65] K. Kinzler,et al. Genes expressed in human tumor endothelium. , 2000, Science.
[66] W. Oyen,et al. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[67] E. Livingston,et al. Human endomucin is an endothelial marker. , 2001, Biochemical and biophysical research communications.
[68] C. Halin,et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. , 2002, Bioconjugate chemistry.
[69] J. Yodoi,et al. Persistent oxidative stress in cancer , 1995, FEBS letters.
[70] F. Baralle,et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. , 1987, The EMBO journal.
[71] F. Peale,et al. Gene expression profiling in an in vitro model of angiogenesis. , 2000, The American journal of pathology.
[72] T. Waldmann,et al. Vascular-Targeted Radioimmunotherapy with the Alpha-Particle Emitter 211At , 2002, Radiation research.
[73] Y. Collan,et al. Prognostic factors in prostate cancer , 2006, Diagnostic pathology.
[74] S. Hauptmann,et al. Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoforms. , 1995, Laboratory investigation; a journal of technical methods and pathology.
[75] D. McDonald,et al. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. , 2003, The American journal of pathology.
[76] W. Oyen,et al. Tumor Targeting with Radiolabeled v 3 Integrin Binding Peptides in a Nude Mouse Model , 2002 .
[77] Grietje Molema,et al. Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature , 1997, Science.
[78] M. Tschöp,et al. Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[79] R. Mulligan,et al. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[80] Clemencia Pinilla,et al. Advances in the use of synthetic combinatorial chemistry: Mixture-based libraries , 2003, Nature Medicine.
[81] P. Rao,et al. Isolation and characterization of the notch ligand delta4. , 2000, Experimental cell research.
[82] J. Szostak,et al. Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures , 1992, Nature.
[83] M. S. Clarke,et al. The identification of proliferation and tumour‐induced proteins in human endothelial cells: A possible target for tumour therapy , 1991, Electrophoresis.
[84] B. Teicher,et al. Murine Endothelial Cell Lines as Models of Tumor Endothelial Cells , 2004, Clinical Cancer Research.
[85] P. Choyke,et al. Imaging of angiogenesis: from microscope to clinic , 2003, Nature Medicine.
[86] N. Tommerup,et al. Molecular Characterization of a Novel Human Hybrid-type Receptor That Binds the α2-Macroglobulin Receptor-associated Protein* , 1996, The Journal of Biological Chemistry.
[87] B. St. Croix,et al. Tumor endothelial markers: new targets for cancer therapy , 2004, Current opinion in oncology.
[88] C. Halin,et al. An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. , 2002, International journal of radiation oncology, biology, physics.
[89] William R Wagner,et al. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine. , 2005, Cancer research.
[90] R Weissleder,et al. Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. , 2000, European journal of cancer.
[91] Dario Neri,et al. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment , 1999, Nature Biotechnology.
[92] Olof Ramström,et al. Drug discovery by dynamic combinatorial libraries , 2002, Nature Reviews Drug Discovery.
[93] Erkki Ruoslahti,et al. αv Integrins as receptors for tumor targeting by circulating ligands , 1997, Nature Biotechnology.
[94] Kenneth J. Hillan,et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.
[95] L. Zardi,et al. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues , 1994, International journal of cancer.
[96] Y. Tsutsumi,et al. Effective Cancer Targeting Using an Anti‐tumor Tissue Vascular Endotheliumspecific Monoclonal Antibody (TES‐23) , 2000, Japanese journal of cancer research : Gann.
[97] Zhen-ping Zhu,et al. Inhibition of Tumor Growth and Metastasis by Targeting Tumor-Associated Angiogenesis with Antagonists to the Receptors of Vascular Endothelial Growth Factor , 2004, Investigational New Drugs.
[98] C. Halin,et al. Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers. , 1999, Journal of immunological methods.
[99] R. Frank. The SPOT-synthesis technique. Synthetic peptide arrays on membrane supports--principles and applications. , 2002, Journal of immunological methods.
[100] D. Hicklin,et al. Active Immunization Against the Vascular Endothelial Growth Factor Receptor flk1 Inhibits Tumor Angiogenesis and Metastasis , 2002, The Journal of experimental medicine.
[101] Rakesh K. Jain,et al. Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.
[102] Daniel S. Miller,et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. , 2000, Archives of pathology & laboratory medicine.
[103] Marc Dellian,et al. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[104] Didier Y. R. Stainier,et al. The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation , 2004, Nature.
[105] N. Bander,et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. , 1997, Cancer research.
[106] H. Augustin,et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.
[107] David A. Cheresh,et al. Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging , 1998, Nature Medicine.
[108] L. Zardi,et al. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues , 1992, International journal of cancer.
[109] Erkki Ruoslahti,et al. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels , 2003, The Journal of cell biology.
[110] L. Dinkelborg,et al. HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY A High-Affinity Human Antibody That Targets Tumoral Blood Vessels , 1999 .
[111] C. Halin,et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature , 2002, Nature Biotechnology.
[112] J. Posey,et al. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. , 2001, Cancer biotherapy & radiopharmaceuticals.
[113] G. Viale,et al. Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. , 2002, The American journal of pathology.
[114] J. Bowsher,et al. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. , 2004, Blood.
[115] J. Rossant,et al. Gene-trap expression screening to identify endothelial-specific genes. , 2004, Blood.
[116] A. Michalowski,et al. The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma. , 1990, British Journal of Cancer.
[117] L. Gold,et al. A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[118] K. Kinzler,et al. Cell surface tumor endothelial markers are conserved in mice and humans. , 2001, Cancer research.
[119] G. V. Vande Woude,et al. Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[120] Dario Neri,et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[121] F. Peale,et al. Stanniocalcin 1 Is an Autocrine Modulator of Endothelial Angiogenic Responses to Hepatocyte Growth Factor* , 2003, Journal of Biological Chemistry.
[122] K. terBrugge,et al. Analysis of Endoglin Expression in Normal Brain Tissue and in Cerebral Arteriovenous Malformations , 2000, Stroke.
[123] F. Felici,et al. Peptide and protein display on the surface of filamentous bacteriophage. , 1995, Biotechnology annual review.
[124] R Bicknell,et al. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. , 2001, Differentiation; research in biological diversity.
[125] S. Stoeckli,et al. Expression of the Extra Domain B of Fibronectin, a Marker of Angiogenesis, in Head and Neck Tumors , 2003, The Laryngoscope.
[126] K. Kairemo,et al. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma--phase I and II study. , 1999, Acta oncologica.
[127] L. Zardi,et al. The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence. , 1992, The Journal of biological chemistry.
[128] R. Falchetto,et al. SpeedScreen: label-free liquid chromatography-mass spectrometry-based high-throughput screening for the discovery of orphan protein ligands. , 2004, Analytical biochemistry.
[129] L. Zardi,et al. Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin , 2002, International journal of cancer.
[130] George Matcuk,et al. Identification of endothelial cell genes by combined database mining and microarray analysis. , 2003, Physiological genomics.
[131] Napoleone Ferrara,et al. Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.
[132] Steffen Helmling,et al. RNAスピーゲルマーによるグレリン活性のin vitro及びin vivo阻害 , 2004 .
[133] Yan Li,et al. Regulation of Notch1 and Dll4 by Vascular Endothelial Growth Factor in Arterial Endothelial Cells: Implications for Modulating Arteriogenesis and Angiogenesis , 2003, Molecular and Cellular Biology.
[134] R. Xiang,et al. DNA vaccines suppress tumor growth and metastases by the induction of anti‐angiogenesis , 2004, Immunological reviews.
[135] F. D. De Braud,et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin , 1999, European Journal of Nuclear Medicine.
[136] S. Vallabhajosula,et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[137] R. Poulsom,et al. EndoPDI, a Novel Protein-disulfide Isomerase-like Protein That Is Preferentially Expressed in Endothelial Cells Acts as a Stress Survival Factor* , 2003, Journal of Biological Chemistry.
[138] David A. Cheresh,et al. Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.
[139] A. Plückthun,et al. Ribosome display: an in vitro method for selection and evolution of antibodies from libraries. , 1999, Journal of immunological methods.
[140] L. Zardi,et al. The fibronectin isoform containing the ed‐b oncofetal domain: A marker of angiogenesis , 1994, International journal of cancer.
[141] M A Konerding,et al. 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon , 2001, British Journal of Cancer.
[142] D. Hicklin,et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.
[143] Michelle R. Arkin,et al. Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.
[144] M. Bednarski,et al. Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.
[145] H. Kosmehl,et al. This is an author version of the contribution published on: Questa è la versione dell’autore dell’opera: Selective targeted delivery of TNFα to tumor blood vessels , 2022 .
[146] I Fisch,et al. "Peptabody": a new type of high avidity binding protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[147] A. Gazdar,et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[148] H. Kosmehl,et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. , 2002, Blood.
[149] Hypoxia and oxidative stress in breast cancer: Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer , 2001, Breast Cancer Research.
[150] F. Burrows,et al. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[151] Jinha M. Park,et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. , 2004, Protein engineering, design & selection : PEDS.
[152] J. Denekamp. Vascular attack as a therapeutic strategy for cancer , 1990, Cancer and Metastasis Reviews.
[153] R. Fleischmann,et al. Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence. , 1995, Nature.
[154] R. Coleman,et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[155] G. Adams,et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. , 2001, Cancer research.
[156] J. Scott,et al. Searching for peptide ligands with an epitope library. , 1990, Science.
[157] R. Hynes,et al. Fibronectin isoform distribution in the mouse. II. Differential distribution of the alternatively spliced EIIIB, EIIIA, and V segments in the adult mouse. , 1996, Cell adhesion and communication.
[158] L. Zardi,et al. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. , 1999, Cancer research.
[159] R. Hynes,et al. Fibronectin isoform distribution in the mouse. I. The alternatively spliced EIIIB, EIIIA, and V segments show widespread codistribution in the developing mouse embryo. , 1996, Cell adhesion and communication.
[160] David E. Gloriam,et al. The human and mouse repertoire of the adhesion family of G-protein-coupled receptors. , 2004, Genomics.
[161] J. Wadenbäck,et al. Cosmix-plexing: a novel recombinatorial approach for evolutionary selection from combinatorial libraries. , 2001, Journal of biotechnology.